Found: 33
Select item for more details and to access through your institution.
Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 15, p. 148, doi. 10.1111/bjh.15397
- By:
- Publication type:
- Article
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 15, p. 193, doi. 10.1111/bjh.15440
- By:
- Publication type:
- Article
Integrated stress response and immune cell infiltration in an ibrutinib‐refractory mantle cell lymphoma patient following ONC201 treatment.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 15, p. 133, doi. 10.1111/bjh.15271
- By:
- Publication type:
- Article
Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia.
- Published in:
- Molecular Medicine, 2019, v. 25, n. 1, p. N.PAG, doi. 10.1186/s10020-018-0069-7
- By:
- Publication type:
- Article
Experience of ibrutinib in a patient with recurrent mantle cell lymphoma with orbital involvement.
- Published in:
- Medicine Science, 2021, v. 10, n. 4, p. 1542, doi. 10.5455/medscience.2021.04.139
- By:
- Publication type:
- Article
Efficacy and safety outcomes of single-agent ibrutinib therapy in chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma.
- Published in:
- European Research Journal, 2023, v. 9, n. 6, p. 1483, doi. 10.18621/eurj.1359362
- By:
- Publication type:
- Article
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 2, p. 33
- By:
- Publication type:
- Article
Paradigm Shift: Ibrutinib plus Rituximab Front-Line Therapy for Patients with CLL Under Age 70.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 1, p. 1
- By:
- Publication type:
- Article
Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab.
- Published in:
- Case Reports in Oncological Medicine, 2020, p. 1, doi. 10.1155/2020/6154213
- By:
- Publication type:
- Article
Bleeding complication following a shave biopsy in a patient taking ibrutinib.
- Published in:
- Dermatology Online Journal, 2022, v. 28, n. 6, p. 1, doi. 10.5070/D328659727
- By:
- Publication type:
- Article
Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.
- Published in:
- Science Signaling, 2019, v. 12, n. 567, p. N.PAG, doi. 10.1126/scisignal.aat4105
- By:
- Publication type:
- Article
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2019, v. 38, n. 1, p. N.PAG, doi. 10.1186/s13046-019-1076-4
- By:
- Publication type:
- Article
Venetoclax as a single agent and in combination with PI3K‐MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 2, p. 298, doi. 10.1111/bjh.15079
- By:
- Publication type:
- Article
Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 4, p. 578, doi. 10.1111/bjh.15567
- By:
- Publication type:
- Article
Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 3, p. 421, doi. 10.1111/bjh.15545
- By:
- Publication type:
- Article
Ibrutinib induces rapid down‐regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia‐related genes in blood and lymph nodes.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 2, p. 212, doi. 10.1111/bjh.15516
- By:
- Publication type:
- Article
What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
- Published in:
- Cell Transplantation, 2020, v. 29, p. 1, doi. 10.1177/0963689720950209
- By:
- Publication type:
- Article
Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-47305-2
- By:
- Publication type:
- Article
Low incidence of ibrutinib discontinuation in real-life experience.
- Published in:
- Review of Medicine / Przeglad Lekarski, 2018, v. 75, n. 12, p. 579
- By:
- Publication type:
- Article
New therapeutic options for hairy cell leukemia.
- Published in:
- Acta Haematologica Polonica, 2022, v. 53, n. 1, p. 39, doi. 10.5603/AHP.a2021.0095
- By:
- Publication type:
- Article
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 4, p. 1, doi. 10.1038/s41408-021-00467-7
- By:
- Publication type:
- Article
Ibrutinib does not prevent kidney fibrosis following acute and chronic injury.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-91491-x
- By:
- Publication type:
- Article
Erratum to “A Case of Bing–Neel Syndrome Successfully Treated with Ibrutinib”.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.
- Published in:
- 2018
- By:
- Publication type:
- journal article
New treatment approaches in relapsing/refractory primary central nervous system lymphomas.
- Published in:
- Annals of Medical of Research, 2022, v. 29, n. 11, p. 1205, doi. 10.5455/annalsmedres.2022.01.042
- By:
- Publication type:
- Article
Late-chronic cardiotoxicity and heart failure caused by ibrutinib: a case report and literature review.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
- Published in:
- Nature Communications, 2017, v. 8, n. 1, p. 1, doi. 10.1038/s41467-017-02329-y
- By:
- Publication type:
- Article
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
- Published in:
- PLoS ONE, 2019, v. 14, n. 2, p. 1, doi. 10.1371/journal.pone.0211228
- By:
- Publication type:
- Article
The Difficult-to-Treat del 17 p Patient—A Case Report in Chronic Lymphocytic Leukemia.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Ibrutinib‐associated T‐cell pseudolymphoma.
- Published in:
- Clinical & Experimental Dermatology, 2019, v. 44, n. 7, p. 828, doi. 10.1111/ced.13907
- By:
- Publication type:
- Article
Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients.
- Published in:
- Current Oncology, 2022, v. 29, n. 4, p. 2792, doi. 10.3390/curroncol29040227
- By:
- Publication type:
- Article
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study.
- Published in:
- Current Oncology, 2022, v. 29, n. 4, p. 2174, doi. 10.3390/curroncol29040176
- By:
- Publication type:
- Article